These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23178753)

  • 1. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
    PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
    Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
    Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
    [No Abstract]   [Full Text] [Related]  

  • 6. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
    Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
    Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G; Klinger M; Schmidt M; Subklewe M
    Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
    Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells.
    Stamova S; Cartellieri M; Feldmann A; Bippes CC; Bartsch H; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Rieber EP; Bachmann M
    Leukemia; 2011 Jun; 25(6):1053-6. PubMed ID: 21415850
    [No Abstract]   [Full Text] [Related]  

  • 16. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
    Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
    Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
    Walter RB
    Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.
    Yan Z; Gu R; Ma H; Chen N; Zhang T; Xu Y; Qiu S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1879-1895. PubMed ID: 39008193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
    Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia.
    Zeng X; Zhang H; Guo J; Yang D; Zhu Y; Liu N; Tang J; Liu T; Zhao X
    Cell Mol Life Sci; 2024 Aug; 81(1):371. PubMed ID: 39196413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.